Ann: First Patient Dosed in MND Phase 1/2 Trial, page-172

First 172 Last

Share
Profile

Follow
Jockthegreat

2,596 Posts.

1422

01/07/23

10:25

Post #: 68566117
Share

Originally posted by Densy: ↑

I'm pretty sure I've posted this before, but here's a reminder of why MPL vs MND looks so promising:

https://www.nature.com/articles/s41598-021-97405-1

For those who want to skip to the punchline...

In plain English, at doses greater than 0.4 micromoles, rapamycin seems to be working to down-regulate the mTOR C1 pathway and induce autophagy in motor neurones, clearing out the build-up of misformed proteins that are a hallmark of MND and 'rescuing' these cells.
But wait!
Once the dose of rapamycin exceeds 1 micromole, it becomes toxic. Toxicity also seems to increase over time, even at lower doses. So, while higher doses and extended treatment times may be better for inducing autophagy (which is what we're chasing) you also poison the patient. This is known as dose limiting toxicity.

This is why MPL look so promising!

As an mTOR inhibitor, preclinical research shows that MPL induces autophagy and clears misfolded proteins in a similar fashion to rapamycin but without with same dose-limiting toxicity. MPL is known to be a pretty benign drug.

As those who've seen the MND webinar will appreciate, a great deal of research and preparation has informed the trial and there are very good reasons to expect big things.

Now add in the apparent ability to more than double life expectancy in canine lymphoma (and how this is likely to translate to human cancer).

Plus the antiviral applications.

Of course I'd love it if PharmAust had an entire drug development department with hundreds of staff that could make it all happen at once - but we don't.

Which means everything takes longer, but it is most definitely happening people.

Cheers

Densy

Expand

An interesting post to revisit while we await the outcome on Tuesday...

PAA Price at posting: 7.5¢ Sentiment: Hold Disclosure: Held
7 Upvote

2 Great analysis

Reply

Top Stories

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

SS1

Sun Silver submits US$60M Silver Paste Funding Application to US DoE

Time for retail therapy buying in the shopping Scentre for hot stocks

Eurozone-based companies find new ways to secure a regional lithium supply

End of FY is a time to juggle wins, losses and capital gains taxes

First 172 Last

Add PAA (ASX) to my watchlist

(20min delay)
Last 21.0¢		Change 0.000(0.00%)		Mkt cap ! $83.14M

Open	High	Low	Value	Volume
21.5¢	21.5¢	21.0¢	$109.7K	513.3K

Buyers (Bids)

No.	Vol.	Price($)
7	281695	20.5¢

Sellers (Offers)

Price($)	Vol.	No.
21.0¢	27964	1

View Market Depth

No.	Vol.	Price($)
7	281695	0.205
12	354540	0.200
4	83692	0.195
14	296234	0.190
3	314594	0.185

Price($)	Vol.	No.
0.210	27964	1
0.215	169058	6
0.220	239679	2
0.230	8488	1
0.235	20000	1

Last trade - 16.10pm 25/06/2024 (20 minute delay)

PAA (ASX) Chart

Ann: First Patient Dosed in MND Phase 1/2 Trial, page-172

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Sun Silver submits US$60M Silver Paste Funding Application to US DoE

Time for retail therapy buying in the shopping Scentre for hot stocks

Eurozone-based companies find new ways to secure a regional lithium supply

End of FY is a time to juggle wins, losses and capital gains taxes

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: First Patient Dosed in MND Phase 1/2 Trial, page-172

Top Stories

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Sun Silver submits US$60M Silver Paste Funding Application to US DoE

Time for retail therapy buying in the shopping Scentre for hot stocks

Eurozone-based companies find new ways to secure a regional lithium supply

End of FY is a time to juggle wins, losses and capital gains taxes

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News